5-Amino-2-Aroylquinolines as highly potent tubulin polymerization inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2309-2313

  Nien, Chih Ying ^a   Chen, Yun Ching ^b   Kuo, Ching Chuan ^b   Hsieh, Hsing Pang ^b   Chang, Chi Yen ^b   Wu, Jian Sung ^b   Wu, Su Ying ^b   Liou, Jing Ping ^a   Chang, Jang Yang ^b,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 AROYLQUINOLINE DERIVATIVE; 5 AMINO 6 METHOXY 2 (3' 4' 5' TRIMETHOXYBENZOYL) QUINOLINE; 5 AMINO 6 METHOXY 2 AROYLQUINOLINE; 6 (3' 4' 5' TRIMETHOXYBENZOYL) QUINOLINE; 6 METHOXY 2 (3' 4' 5' TRIMETHOXYBENZOYL) QUINOLINE; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 77949378899     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm900685y     Document Type: Article

References (33)

1. Jordan, M. A.; Wilson, L. Microtubules as a Target for Anticancer Drugs. Nat. Rev. Cancer 2004, 4, 253-265.
2. (a) Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an Agent that Displays Potent and Selective Toxicity toward Tumor Vasculature. Cancer Res. 1997, 57, 1829-1834.
3. (b) Hinnen, P.; Eskens, F. A. L. M. Vascular Disrupting Agents in Clinical Development. Br. J. Cancer 2007, 96, 1159-1165.
4. (c) Lippert, J. W., III. Vascular Disrupting Agents. Bioorg. Med. Chem. 2007, 15, 605-615.
5. (d) Siemarm, D. W. Vascular-Targeted Therapies in Oncology. John Wiley & Sons: New York, 2006.
6. (e) Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marme, D.; LoRusso, P. M. Differentiation and Definition of Vascular-Targeted Therapies. Clin. Cancer Res. 2005, 11, 416-420.
7. (f) Gaya, A. M.; Rustin, G. J. Vascular Disrupting Agents: a New Class of Drug in Cancer Therapy. Clin. Oncol. 2005, 17, 277-290.
8. (g) Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
9. (h) Patterson, D. M.; Rustin, G J. S. Vascular Damaging Agents. Clin. Oncol. 2007, 19, 443-456.
10. (i) Siemann, D. W.; Chaplin, D. J.; Walicke, P. A. A Review and Update of the Current Status of the VasculatureDisabling Agent Combretastatin-A4 Phosphate (CA4P) Expert Opin. Investig. Drugs 2009, 18, 189-197.
11. (j) Tozer, G. M.; Akerman, S.; Cross, N. A.; Barber, P. R.; Bjömdahl, M. A.; Greco, O.; Harris, S.; Hill, S. A.; Honess, D. J.; Ireson, C. R.; Pettyjohn, K. L.; Prise, V. E.; ReyesAldasoro, C. C. Blood Vessel Maturation and Response to VascularDisrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors. Cancer Res. 2008, 68, 2301-2311.
12. (a) Mauer, A. M.; Cohen, E. E.; Ma, P. C.; Kozloff, M. F.; Schwartzberg, L.; Coates, A. I.; Qian, J.; Hagey, A. E.; Gordon, G. B. A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer. J. Thorac. Oncol. 2008, 3, 631-636.
13. (b) Fox, E.; Maris, J. M.; Widemann, B. C.; Goodspeed, W.; Goodwin, A.; Kromplewski, M.; Fouts, M. E.; Medina, D.; Cohn, S. L.; Krivoshik, A.; Hagey, A. E.; Adamson, P. C.; Balis, F. M. A Phase I Study of ABT751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. Clin. Cancer Res. 2008, 14, 1111-1115.
14. (a) Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal Chemistry of Combretastatin A4: Present and Future Directions. J. Med. Chem. 2006, 49, 3033-3044.
15. (b) Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical Design of Antimitotic Agents Based on Combretastatins. Curr. Pharm. Des. 2005, 11, 1655-1677.
16. (c) Li, Q.; Sham, H. L. Discovery and Development of Antimitotic Agents That Inhibit Tubulin Polymerisation for the Treatment of Cancer. Expert Opin. Ther. Patents 2002, 12, 1663-1702.
17. (d) Mahindroo, N; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin Agents for the Treatment of Cancer-A Medicinal Chemistry Update. Expert. Opin. Ther. Patents 2006, 16, 647-691.
18. (e) Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current Development Status of Small-Molecule Vascular Disrupting Agents. Curr. Opin. Investig. Drugs 2006, 7, 522-528.
19. (f) Romagnoli, R.; Baraldi, P. G.; Sarkar, T.; Carrion, M. D.; Cara, C. L.; Cruz-Lopez, O.; Preti, D.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Cristina, A. D.; Zonta, N.; Balzarini, J.; Brancale, A.; Hsieh, H. P.; Hamel, E. Synthesis and Biological Evaluation of 1-Methyl-2-(3′,4′,5′- trimethoxybenzoyl)-3aminoindoles as a New Class of Antimitotic Agents and Tubulin Inhibitors. J. Med. Chem. 2008, 51, 1464-1468.
20. (g) Liou, J. P.; Wu, C. Y.; Hsieh, H. P.; Chang, C. Y.; Chen, C. M.; Kuo, C. C.; Chang, J. Y. 4- and 5-Aroylindoles as Novel Classes of Potent Antitubulin Agents. J. Med. Chem. 2007, 50, 4548-4552.
21. (h) Prinz, H.; Schmidt, P.; Böhm, K. J.; Baasner, S.; Müller, K.; Unger, E.; Gerlach, M.; Günther, E. G. 10-(2-oxo-2-Phenylethylidene)- 10H-anthracen-9-ones as Highly Active Antimicrotubule Agents: Synthesis, Antiproliferative Activity, and Inhibition of Tubulin Polymerization. J. Med. Chem. 2009, 52, 1284-1294.
22. (i) Liou, J. P.; Wu, Z. Y.; Kuo, C. C.; Chang, C. Y.; Lu, P. Y.; Chen, C. M. ; Hsieh, H. P. ; Chang, J. Y Discovery of 4-Amino and 4-Hydroxy1- Aroylindóles as Potent Tubulin Polymerization Inhibitors. J. Med. Chem. 2008, 51, 4351-4355.
23. (j) Reddy, G R.; Kuo, C. C.; Tan, U. K.; Coumar, M. S.; Chang, C. Y.; Chiang, Y K.; Lai, M. J.; Wu, S. Y.; Chang, J. Y.; Liou, J. P.; Hsieh, H. P. Synthesis and StructureActivity Relationships of 2-Amino and 2-Hydroxy-l-Aroylnaphthalenes as Potent Antitubulin Agents. J. Med. Chem. 2008, 51, 8163-8167.
24. (k) Simoni, D.; Romagnoli, R.; Barrichello, R.; Rondanin, R.; Grisolia, G.; Eleopra, M.; Rizzi, M.; Tolomeo, M.; Giannini, G.; Alloatti, D.; Castorina, M.; Marcellini, M.; Pisano, C. Novel A-Ring and B-Ring Modified Combretastatin A-4 (CA-4) Analogues Endowed with Interesting Cytotoxic Activity. J. Med. Chem. 2008, 51, 6211-6215.
25. Joule, J. A.; Mills, K.; Smith, G. F. Heterocyclic Chemistry, 3rd ed.; Chapman & Hall: London, 1995; Chapter 6.
26. (a) Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H. M.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Analogues of (Z)l-(4-Methoxyphenyl)-2-(3, 4,5-trimethoxyphenyl)ethane as Potential Cytotoxic and Antimitotic Agents. J. Med. Chem. 1992, 35, 2293-2306.
27. (b) Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate. J. Med. Chem. 1998, 41, 1688-1695.
28. (c) Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents That Inhibit Tubulin Polymerization. J. Med. Chem. 1991, 34, 2579-2588.
29. (d) Pettit, G R.; Anderson, C. R.; Herald, D. L.; Jung, M. K.; Lee, D. J.; Hamel, E.; Pettit, R. K. Antineoplastic Agents. 487. Synthesis and Biological Evaluation of the Antineoplastic Agents 3,4-Methylenedioxy-5, 4′-dimethoxy-3′-amino-Z-stilbene and Derived Amino Acid Amides. J. Med. Chem. 2003, 46, 525-531.
30. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagaau, T.; Tsukahara, K.; Iijima, A.; Kitoh, K. Novel Sulfonamides as Potential, Systemically Active Antitumor Agents. J. Med. Chem. 1992, 35, 2496-2497.
31. Liou, J. P.; Hsu, K. S.; Kuo, C. C.; Chang, C. Y.; Chang, J. Y. A Novel Oral Indoline-Sulfonamide Agent, J30, Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule. J. Pharmacol. Exp. Ther. 2007, 323, 398-405.
32. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chang, J. Y. BPR0L075, a Novel Synthetic Indole Compound with Antitumoral Activity in Vivo. Cancer Res. 2004, 64, 4621-4628.
33. Because the form of evaluations involves more than binding to the receptor or target, for example, transport and solubility, we use this term, structure-cell inhibitory activity, instead of structureactivity relationship.